natgillin/translations-raw huggingface dataset:
The above recommendations are based on a review of the available evidence of safety and efficacy of oral bromocriptine for prevention and suppression of lactation. 
Zgornja priporočila temeljijo na pregledu razpoložljivih dokazov o varnosti in učinkovitosti peroralnega bromokriptina pri preprečevanju in zaviranju laktacije.
• Use is contraindicated for patients with uncontrolled hypertension, hypertensive disorders of pregnancy (including eclampsia, pre-eclampsia or pregnancy-induced hypertension), hypertension post-partum and in the puerperium, a history of coronary artery disease or other severe cardiovascular conditions, or a history of severe psychiatric disorders. 
• Uporaba je kontraindicirana pri bolnicah z nenadzorovano hipertenzijo, hipertenzivnimi motnjami v nosečnosti (vključno z eklampsijo, preeklampsijo in hipertenzijo zaradi nosečnosti), hipertenzijo po porodu in v puerperiju, boleznijo koronarnih arterij ali drugimi hudimi srčno-žilnimi boleznimi v anamnezi ali z anamnezo hudih psihiatričnih motenj.
• Women who are at greater risk of side effects, such as those who have a condition that increases blood pressure, or who have a history of serious mental illness, should not take bromocriptine. 
• Ženske, pri katerih obstaja večje tveganje za neželene učinke, na primer ženske z boleznijo, ki zvišuje krvni tlak, in tiste, ki so kdaj imele resne psihiatrične motnje, bromokriptina ne smejo jemati.
As a result, bromocriptine prevents the secretion of prolactin, thereby preventing or suppressing milk production. 
Bromokriptin tako preprečuje izločanje prolaktina in s tem prepreči ali zavira tvorjenje mleka.
• Bromocriptine should not be used to relieve symptoms of pain or swelling of the breasts after childbirth when such symptoms can be managed by measures such as breast support or applying ice, and the use of painkillers if needed. 
• Bromokriptin se ne sme uporabljati za lajšanje simptomov bolečine v dojkah ali nabrekanja dojk po porodu, kadar je te simptome mogoče obvladati z ukrepi, kot so podpiranje dojk ali ledeni obkladki, in z uporabo protibolečinskih zdravil, če je to potrebno.
The CMDh agreed that the medicines should only be used for this purpose (in strengths up to 2.5 mg) when there are compelling medical reasons for stopping lactation, such as the need to avoid further distress after loss of the baby during or just after childbirth, or in mothers with HIV infection, who should not breastfeed. 
Skupina CMDh se je strinjala, da se lahko zdravila za ta namen uporabljajo (v jakostih do 2,5 mg) samo, kadar obstajajo prepričljivi zdravstveni razlogi za zaustavitev laktacije, na primer, da se prepreči nadaljnji stres po izgubi otroka med porodom ali takoj po njem ali če je mati okužena z virusom HIV in zato ne sme dojiti.
• Bromocriptine should not be used for the routine suppression of lactation, nor for the relief of symptoms of post-partum pain and engorgement, which can be adequately treated with nonpharmacological intervention (such as firm breast support, ice application) and simple analgesics. 
• Bromokriptin se ne sme uporabljati za rutinsko zaviranje laktacije niti za lajšanje simptomov poporodne bolečine in nabreklosti, ki jih je mogoče ustrezno zdraviti z nefarmakološkimi ukrepi (na primer s podpiranjem dojk ali ledenimi obkladki) in s preprostimi analgetiki.
• Bromocriptine should only be used orally in strengths up to 2.5 mg to inhibit lactation when medically indicated, such as in case of intrapartum loss, neonatal death or HIV infection of the mother. 
• Bromokriptin se lahko uporablja samo peroralno v jakostih do 2,5 mg za zaviranje laktacije, kadar so za to prisotne zdravstvene indikacije, na primer v primeru izgube otroka med porodom, smrti novorojenčka ali okužbe matere z virusom HIV.
Bromocriptine is used to prevent or suppress milk production in women who have given birth. 
Bromokriptin se uporablja za preprečevanje ali zaviranje tvorjenja materinega mleka pri ženskah po porodu.
The following recommendations (some of which are already included in the product information) should be borne in mind when prescribing bromocriptine for the prevention or suppression of lactation. 
Pri predpisovanju bromokriptina za preprečevanje ali zaviranje laktacije je treba upoštevati priporočila, navedena v nadaljevanju (nekatera od teh so že vključena v informacije o zdravilu).
This summary was last updated in January 2014. 
Povzetek je bil nazadnje posodobljen januarja 2014.
If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR). 
Če želite več informacij o podlagi za priporočila CVMP, preberite znanstveno razpravo (ki je prav tako del EPAR).
The European Commission granted a marketing authorisation valid throughout the European Union, for Equisolon on 12/03/2014. 
Evropska komisija je dovoljenje za promet z zdravilom Equisolon, veljavno po vsej Evropski uniji, odobrila 12/03/2014.
The use of prednisolone in horses with RAO has been well described in the scientific literature. 
Uporaba prednizolona pri konjih z RAO je dobro opisana v znanstveni literaturi.
Other information about Equisolon: 
Druge informacije o zdravilu Equisolon:
This document is a summary of the European Public Assessment Report. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR).
A field study was conducted in which the same 8 horses with RAO after exposure to hay participated in 4 treatment periods receiving either no treatment or Equisolon at three different doses, each for ten days. 
Opravili so terensko študijo, v kateri je istih 8 konjev z RAO po izpostavljenosti senu sodelovalo v 4 obdobjih zdravljenja, med katerimi niso prejeli nobenega zdravljenja ali so prejemali zdravilo Equisolon v treh različnih odmerkih po deset dni.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Equisolon exceed the risks for the approved indication and recommended that Equisolon be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Equisolon večje od z njim povezanih tveganj za odobrene indikacije, in priporočil, da se zanj odobri dovoljenje za promet.
The product should not be shaken to prevent dust formation. 
Zdravilo se ne sme stresati, da se prepreči tvorjenje prahu.
The medicine should not be given to horses by pregnant women as there is a risk of malformation to the unborn baby. 
Konjem zdravila ne smejo dajati nosečnice, saj obstaja tveganje malformacije (nepravilnosti v razvoju) pri nerojenem otroku.
The main measures of effectiveness were clinical signs of RAO disease as well as the amount of fluid and immune cells in the airways and the air pressure in the lungs. 
Glavna merila učinkovitosti so bili klinični znaki bolezni RAO, količina tekočine in imunskih celic v dihalnih poteh ter zračni tlak v pljučih.
What benefit has Equisolon shown during the studies? 
Kakšne koristi je zdravilo Equisolon izkazalo med študijami?
The most common side effects (seen in more than 1 in 10 horses) with Equisolon are suppression of production of cortisol (a natural corticosteroid important in the body's response to stress), and an increase in the level of triglycerides (a type of fat) in the blood. 
Najpogostejša neželena učinka (pojavita se pri več kot 1 od 10 konjev) zdravila Equisolon sta zaviranje tvorbe kortizola (naravnega kortikosteroida s pomembno vlogo pri odzivu telesa na stres) in povišanje ravni trigliceridov (vrste maščob) v krvi.
RAO is a chronic (long-term) allergic condition in which horses wheeze, cough and have difficulty in breathing. 
RAO je kronično (dolgotrajno) alergijsko stanje, pri katerem imajo konji piskanje v prsnem košu, kašelj in oteženo dihanje.
Treatment with prednisolone at the recommended dose of 1 mg per kg bodyweight over ten days in combination with environmental control resulted in significant improvements in fluid in the airways and clinical signs associated with RAO. 
Zdravljenje s prednizolonom v priporočenem odmerku 1 mg na kg telesne mase, ki je trajalo deset dni, je v kombinaciji z nadzorovanjem okoljskih pogojev povzročilo pomembno izboljšanje količine tekočine v dihalnih poteh in kliničnih znakov, povezanih z RAO.
The active substance in Equisolon, prednisolone, is a corticosteroid, a medicine that acts to reduce the activity of the immune system. 
Zdravilna učinkovina v zdravilu Equisolon, prednizolon, je kortikosteroid, ki deluje tako, da zmanjša dejavnost imunskega sistema.
The environmental measures include keeping horses outside as much as possible or improving the ventilation in the stable, soaking hay or feeding silage (fermented grass) and using bedding with a minimum of dust in the stable. 
Okoljski ukrepi vključujejo čim daljše zadrževanje konjev na prostem ali izboljšanje prezračevanja v staji, namakanje sena ali krmilne silaže (fermentirane trave) in uporabo stelje z minimalno vsebnostjo prahu.
What is the risk associated with Equisolon? 
Kakšna tveganja so povezana z zdravilom Equisolon?
Equisolon is used to treat recurrent airway obstruction (RAO or heaves) in horses in combination with environmental measures. 
Zdravilo Equisolon se uporablja za zdravljenje ponavljajoče se obstrukcije dihal (recurrent airway obstruction - RAO ali naduhe) pri konjih v kombinaciji z okoljskimi ukrepi.
In horses with RAO, the immune system (the body's natural defences) over-reacts to triggering substances (antigens) that are present in dust that the horse breathes in. 
Pri konjih z RAO imunski sistem (naravna obramba telesa) čezmerno reagira na sprožilce (antigene), prisotne v prahu, ki ga vdihavajo konji.
Prednisolone 
Equisolon prednizolon
In addition to treatment with prednisolone, the exposure to organic dust was reduced by substituting hay with silage and by improving the ventilation in the stable. 
Poleg zdravljenja s prednizolonom so izpostavljenost organskemu prahu zmanjšali z zamenjavo sena s silažo in izboljšanjem prezračevanja v staji.
It is also the time allowed after administration of the medicine before milk can be used for human consumption. 
To je tudi čas, ki mora preteči po dajanju zdravila, preden se lahko mleko uporabi za prehrano ljudi.
The benefit-risk balance may be found in the scientific discussion module of this EPAR. 
Razmerje med koristmi in tveganji je na voljo v modulu znanstvene razprave v tem povzetku.
This results in inflammation and blockage of the airways inside the lungs, leading to difficulty in breathing. 
To povzroči vnetje in zaprtje dihalnih poti v pljučih, kar privede do oteženega dihanja.
Equisolon is a veterinary medicine that contains the active substance prednisolone. 
Equisolon je zdravilo za uporabo v veterinarski medicini, ki vsebuje zdravilno učinkovino prednizolon.
Equisolon should be mixed with a small amount of food and given by mouth at a dose of 1 mg prednisolone per kg bodyweight once a day. 
Zdravilo Equisolon je treba zmešati z majhno količino krme in dati peroralno (prek ust) v odmerku 1 mg prednizolona na kg telesne mase enkrat na dan. Odmerjanje lahko traja deset zaporednih dni.
For a full list of all side effects reported with Equisolon, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Equisolon, glejte navodilo za uporabo.
It is available as a powder to be given by mouth. 
Na voljo je v obliki praška, ki se daje peroralno (prek ust).
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption. 
Obdobje karence je čas, ki mora preteči po dajanju zdravila, preden se lahko žival zakolje in njeno meso uporabi za prehrano ljudi.
This decreases inflammation, thereby helping to keep the airways clear and allowing the horse to breathe more easily. 
To zmanjša vnetje in posledično pomaga pri vzdrževanju prehodnosti dihalnih poti ter olajša dihanje.
Equisolon must not be used in horses with viral or fungal infections, gastrointestinal or corneal ulcers or in pregnant mares. 
Zdravilo Equisolon se ne sme uporabljati pri konjih z virusnimi ali glivičnimi okužbami, razjedami v prebavilih ali na roženici in pri brejih kobilah.
Why has Equisolon been approved? 
Zakaj je bilo zdravilo Equisolon odobreno?
The withdrawal period for Equisolon for meat is ten days. 
Karenca zdravila Equisolon pri mesu je deset dni.
Equisolon should not be used in mares producing milk for human consumption. 
Zdravilo Equisolon se ne sme uporabljati pri kobilah, katerih mleko je namenjeno prehrani ljudi.
How has Equisolon been studied? 
Kako je bilo zdravilo Equisolon raziskano?
How does Equisolon work? 
Kako zdravilo Equisolon deluje?
What is Equisolon used for? 
Za kaj se zdravilo Equisolon uporablja?
What is Equisolon? 
Kaj je zdravilo Equisolon?
These measures should help to protect the environment. 
Taki ukrepi pomagajo varovati okolje.
However, these reactions may be more severe and/or last longer. 
Vendar pa so te reakcije lahko resnejše in/ali dlje trajajo.
If such reactions occur appropriate treatment is recommended. 
Če nastanejo take reakcije, se priporoča ustrezno zdravljenje.
DATE OF REVISION OF THE TEXT 
DATUM REVIZIJE BESEDILA
Protect from light. 
Zaščitite pred svetlobo.
EXP {month/year} 
EXP {mesec/leto}
Duration of immunity: 1 year. 
Trajanje imunosti: 1 leto.
Avoid accidental self-injection or contact with the eyes. 
Izogibajte se nenamernemu samo-injiciranju ali stiku z očmi.
In very rare cases a transient acute hypersensitivity reaction may occur. 
V zelo redkih primerih se lahko pojavi prehodna akutna preobčutljivostna reakcija.
Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination. 
Vsaka taka oteklina je bodisi izginila ali pa se znatno zmanjšala v 14 dneh po cepljenju.
Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening. 
Take reakcije se lahko razvijejo v resnejše stanje (anafilakso), ki lahko ogrozi življenje.
1 Antigenic mass ELISA units. 
1 ELISA enote mase antigena
Onset of immunity: 3 weeks. 
Nastop imunosti: 3 tedni.
Interaction with other medicinal products and other forms of interaction: 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
The CVMP at their meeting on 17-19 January 2017 decided that one further five-year renewal was required in view of the outstanding pharmacovigilance concerns regarding serious adverse events that were undergoing evaluation at the time of the renewal procedure. 
CVMP se je na sestanku v dnevih 17.-19. januarja odločila, da je potrebno še eno nadaljnje podaljšanje zaradi izrednih problemov farmakovigilance glede resnih neželenih učinkov, ki so bili ugotovljeni v času postopka podaljšanja.
PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 
PREPOVED PRODAJE, OSKRBE IN/ALI UPORABE
4.7 Use during pregnancy, lactation or lay 
4.7 Uporaba v obdobju brejosti, laktacije ali nesnosti
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 
Če opazite kakršne koli resne stranske učinke ali tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite, da zdravilo ni delovalo, obvestite svojega veterinarja.
0.1 mg. Colourless suspension. 
0,1 mg Brezbarvna suspenzija
Can be used during pregnancy. 
Lahko se uporablja v obdobju brejosti.
Colourless suspension. 
Brezbarvna suspenzija.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni stranu Evropske agencije za zdravila (http://www.ema.europa.eu/ ).
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE 
BESEDILO “SAMO ZA ŽIVALI” IN POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, če je smiselno
(*) In case of high level of maternally derived antibodies, first vaccination is recommended at 9 weeks of age. 
(*) V primeru visokega titra maternalnih protiteles se prvo cepljenje priporoča pri starosti 9 tednov.
Store in a refrigerator (2 °C - 8 °C). 
Shranjujte v hladilniku (2 °C - 8 °C).
Do not mix with any other veterinary medicinal product except those mentioned in section 4.8. 
Ne mešajte z nobenim drugim zdravilom razen s tistimi, ki so navedeni v poglavju 4.8.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil za uporabo v veterinarski medicini, je treba odstraniti v skladu z lokalnimi zahtevami.
A small transient swelling at the site of injection (≤ 4 cm), which can occasionally be firm and painful on palpation, has been observed very commonly in clinical studies. 
Majhno prehodno oteklino na mestu injiciranja (≤ 4 cm), ki je včasih lahko trda in boleča na otip, so v kliničnih študijah opazili zelo pogosto.
0.1 mg. For the full list of excipients, see section 6.1. 
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Date of last renewal: 13/03/2017. 
Datum pridobitve dovoljenja za promet: 16/ 07/ 2012 Datum zadnjega podaljšanja: 13/03/2017
Name and address of the manufacturer of the biological active substances 
Ime in naslov proizvajalca bioloških učinkovin
SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use. 
POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A) Pred uporabo preberite navodilo za uporabo.
SPECIAL STORAGE CONDITIONS Store in a refrigerator. 
Shranjujte v hladilniku.
Overdose (symptoms, emergency procedures, antidotes): 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi)
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. 
Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini razen z zgoraj omenjenimi.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV
Revaccination: Dogs should be re-vaccinated annually with one dose (1 ml) of vaccine. 
Revakcinacija: Pse ponovno cepimo vsako leto z enim odmerkom (1 ml) cepiva.
A mild and transient increase in body temperature (≤ 1 °C) has been observed very commonly in clinical studies for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. 
Rahlo in prehodno povišanje telesne temperature (≤ 1°C), ki je trajalo nekaj dni po cepljenju, so zelo pogosto opazili v kliničnih študijah , nekateri mladiči so bili manj aktivni in/ali so imeli zmanjšan apetit.
Do not use this veterinary medicinal product after the expiry date which is stated on the label. 
Tega zdravila za uporabo v veterinarski medicini ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
In case of ocular irritation seek medical advice immediately and show the package leaflet or the label to the physician. 
V primeru draženja oči se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
Shelf life of the veterinary medicinal product as packaged for sale: 21 months. 
Rok uporabnosti zdravila v pakiranju za prodajo: 21 mesecev
Type I glass vial of 1 ml (1 dose) or 10 ml (10 doses) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap. 
Steklena viala tipa I po 1 ml (1 odmerek) ali 10 ml (10 odmerkov), zaprta z zamaškom iz halogenobutilne gume in zatesnjena z aluminijasto zaporko s šifro.
SPECIAL STORAGE PRECAUTIONS 
POSEBNA NAVODILA ZA SHRANJEVANJE
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
Shelf life after first opening the immediate container: 10 hours. 
Rok uporabnosti po prvem odpiranju stičnega vsebnika: 10 ur
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
- občasni (pri več kot 1, toda manj kot 10 živalih od 1.000 zdravljenih živali) - redki (pri več kot 1 toda manj kot 10 živalih od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primere).
Special precautions to be taken by the person administering the veterinary medicinal product to animals 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo
Vaccination scheme: Basic vaccination: The first vaccination can be administered from 6 to 9(*) weeks of age and the second vaccination from 10 to 13 weeks of age. 
Osnovno cepljenje: Prvič lahko cepimo pri starosti od 6 do 9(*) tednov, drugič pa pri starosti od 10 do 13 tednov.
In very rare cases, clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia, or immune-mediated polyarthritis have been reported. 
V zelo redkih primerih so poročali o kliničnih znakih imunsko pogojene hemolitične anemije, imunsko pogojene trombocitopenije ali imunsko pogojenega poliartritisa.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION 
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA
MANUFACTURER'S BATCH NUMBER Lot {number} 
IZDELOVALČEVA ŠTEVILKA SERIJE
Not applicable. 
Ni smiselno.
When mixed with these Nobivac vaccines, the demonstrated safety and efficacy claims for Nobivac L4 are no different from those described for Nobivac L4 alone. 
Kadar se cepivo meša s temi cepivi Nobivac, se podatki o varnosti in učinkovitosti za Nobivac L4 ne razlikujejo od tistih, ki so opisani za samo cepivo Nobivac L4.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products 
6.6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi, ki nastanejo pri uporabi teh zdravil
C. STATEMENT OF THE MRLs Not applicable. 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) Ni smiselno.
Read the package leaflet before use. 
Pred uporabo preberite navodilo za uporabo.
IMMUNOLOGICAL PROPERTIES 
IMUNOLOŠKE LASTNOSTI
When mixed with Nobivac vaccines containing canine parainfluenza virus at annual revaccination, it has been established that there is no interference with the anamnestic response induced by the injectable canine parainfluenza virus component. 
Kadar se to cepivo meša s cepivi Nobivac, ki vsebujejo virus pasje parainfluence, pri letni revakcinaciji, je bilo ugotovljeno, da to ne vpliva na anamnestični odziv, ki ga sproži injicirana komponenta virusa pasje parainfluence.
Shelf life after reconstitution of Nobivac vaccines according to directions: 45 mins. 
Rok uporabnosti po rekonstituciji cepiva Nobivac v skladu z navodili: 45 minut
The mixed vaccines should be at room temperature (15°C - 25°C) before they are administered by subcutaneous injection. 
Mešana cepiva naj bodo pri sobni temperaturi (15°C - 25°C), preden jih damo subkutano.
Before use, ensure that the vaccine is at room temperature (15°C - 25°C). 
Subkutano dajanje Pred uporabo zagotovite, da je cepivo na sobni temperaturi (15°C - 25°C).
Pack sizes: 
Velikosti pakiranj:
Incompatibilities: Do not mix with any other veterinary medicinal products except the above mentioned vaccines. 
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini razen z zgoraj navedenimi cepivi.
MARKETING AUTHORISATION NUMBER(S) 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET
Special warnings for each target species: Vaccinate healthy animals only. 
4.4 Posebna opozorila za vsako ciljno živalsko vrsto Cepite samo zdrave živali.